Global Goals

Technology Driven

Focused on Quality and Delivery

About Us

BrightWay Pharmaceutical Manufacturing Company is a group of companies with a long history of experience in providing best technological process solutions to the pharmaceutical, Biotechnology and Cosmetic industries.

The plant has an annual capacity of more than 3 billion oral solid dosage formulations. With an enviable location on the easily accessible at Atlas House, the plant is a preferred destination for contract manufacturing and site variation for general category tablets, capsules and sachets.

The facility has been built in line with latest regulatory requirements with a view to comply with United Kingdom and European Manufacturing Law.

It is equipped with sophisticated UK & USA Pharmaceutical Law automated machines at each step of manufacturing.

Our strength is the team with wide experience in internationally reputed environment including contract manufacturing related aspects.

BrightWay Pharmaceutical Manufacturing Company is poised to be a leading destination in contract manufacturing space in United Kingdom and all over Europe.

Partnering Advantages

Brand new unit matching all relevant norms of regulatory authorities.

  • Dedicated contract manufacturing operations for regulated markets.
  • No conflict of interests as BrightWay Pharmaceutical Manufacturing Company present in the European & American market with own products or brands.
  • Professional corporate set-up ensures efficient management of operations
  • Relevant experience: BrightWay Pharmaceutical Manufacturing Company has experience of regulatory processes ISO certification and UK Pharmaceutical Law aspects.
  • Financially sound to support the investments required.
  • Layout to match the regulatory requirements as per UK-FDA, WHO and other international regulatory agencies.
  • Logical man and material movement to ensure unidirectional flow avoiding cris cross.
  • Flexibility in operations, design of various parameters ensures quick changeover between products.
  • Separate two lines, one for tablets and one for capsules, minimizing the risk of contamination or cross-contamination.